• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > Amid disruption in health care, private equity is poised to put its cash to work

Amid disruption in health care, private equity is poised to put its cash to work

Apr. 10, 2020 by Matt Wolf

  • email
  • Twitter
  • Facebook
  • Linkedin

As the human and economic toll of the coronavirus pandemic has mounted, companies across industries have fallen into distress, including in the health care sector. As they look for a lifeline, private equity firms are in position to put some of their significant cash on hand to work.

Many of these deals will be found in private capital markets. But the public markets can also provide a leading indicator of the deal-making to come. Revenue and earnings guidance have been lowered or removed, distressed bond trading has skyrocketed and the health care operating environment grows more challenging by the day.

Corporate guidance can indicate executives’ overall outlook on the economy, the sector in which they operate and their own companies. So far this year, 135 publicly traded U.S. companies with a combined market capitalization of more than $1.5 trillion have lowered revenue guidance.

Of those 135 companies, 29 are in the health care sector, the largest of which include Bristol-Myers Squibb, Gilead Sciences and Centene. In addition, 73 more companies, with a market capitalization of $4.8 trillion, withdrew guidance altogether, including Boston Scientific and Quest Diagnostics, an important company in coronavirus testing.

From the fixed income perspective, we can look to the prevalence of distressed bonds. The number of distressed issues traded, according to TRACE, is now the highest in the history of the index, eclipsing levels reached during the financial crisis. A higher volume of distressed bonds has a clear negative correlation to overall financial conditions.

More specific to the health care ecosystem, there has been extreme volatility in the spread between high-yield and investment-grade municipal bonds. Since January 1, the spread between high yield and investment grade municipal bonds has exceeded 1,000 basis points, a multiyear high.

While this spread has surged in prior periods, it has generally not been coupled with a rapidly changing health care environment.

In response to the coronavirus outbreak, the federal government is pouring hundreds of billions of dollars into the health care system while the Department of Health and Human Services and the Centers for Medicare and Medicaid Services briskly alter reimbursement, prior authorization and other rules. At the same time, providers and patients are delaying and canceling procedures, putting further strain on the health care ecosystem.

Some companies in the health care sector will emerge leaner and stronger on the other side of the pandemic. Others will not. This will create opportunities for investors, as periods of economic dislocation always do.

Private equity firms in particular stand poised to capitalize on such opportunities. Health care private equity funds of all sizes in the U.S. have $165 billion of dry powder. Over the short term, this capital has been committed by limited partners, so the “demand” for acquiring health care companies is fixed. And given U.S. demographic trends and susceptibility to future disruption, we do not expect investors’ demand for health care to meaningfully decline over the medium to long-term.

As the financial and competitive conditions force more health care companies of all kinds to liquidate or seek outside financing, the supply of investment opportunities will increase. This will push down valuation multiples since the demand will not likely decline. In other words, not only will the number of potential deals expand but the price that both strategic and financial buyers pay will also decline.

The takeaway

As the dust settles from the initial shock of the coronavirus pandemic, investors must prepare for the new normal of deal making: lower multiples and distressed assets.

For more information on how the coronavirus is affecting midsize businesses, please visit the RSM Coronavirus Resource Center

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Scrutiny on private equity investment in health care increases

    As private equity groups continue to invest in the health care industry, their business practices are falling under increasing scrutiny from lawmakers, researchers and the news media.

  • Private equity's role in health care gains interest in Congress

    A bill is working its way through Congress that could have an impact on health care providers, particularly those owned by private equity firms.

  • Hospital hallway
    Medicaid expansion to lift health care in 2019

    Four states—Idaho, Nebraska, Utah and Montana— included Medicaid expansion on their ballots in 2018’s midterm elections. Montana’s ballot item was a renewal of expansion, which failed; the three other states saw Medicaid expansion initiatives pass, and we expect…

Filed Under: Coronavirus, Health Care Tagged With: coronavirus, Covid-19, health care, privage equity

About Matt Wolf

@MattWolfHC

Matt leads RSM’s health care valuation consulting group. In this capacity, Matt helps health care clients evaluate mergers, acquisitions, joint ventures, and other growth strategies.

In January 2018, Matt was selected as a senior analyst RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions impacting middle market leaders. Matt’s focus is the health care and life sciences space.

Primary Sidebar

Read RSM analysts’ industry coverage of coronavirus.

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Health Care articles

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021

The case for assistance to state and local governments

Jan. 12, 2021

CHART OF THE DAY: As vaccination begins, health care remains underemployed

Jan. 11, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences